Celgene (CELG) Tops Q3 EPS by 7c, Updates Guidance

Celgene (NASDAQ: CELG) reported Q3 EPS of $2.29, $0.07 better than the analyst estimate of $2.22. Revenue for the quarter came in at $3.89 billion versus the consensus estimate of $3.83 billion.

GUIDANCE:

Celgene sees FY2018 EPS of $8.75-$8.80, versus the consensus of $8.76. Celgene sees FY2018 revenue of $15.2 billion, versus the consensus of $15.17 billion.

For earnings history and earnings-related data on Celgene (CELG) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• InspireMD (NSPR) Tops Q2 EPS by 1c
• Is Treasury selloff a major issue for stock market bulls?